title: Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.
abstract: Patients with hematologic malignancies were conditioned using a rabbit antithymocyte globulin-based reduced-intensity conditioning regimen for allogeneic stem cell transplantation. Donor-derived CD3(+) cell count (ddCD3), a product of CD3(+) cell chimerism and absolute CD3(+) cell count, when <110/μL at 8 weeks post-stem cell transplantation predicted a high risk of sustained mixed chimerism and relapse. Alternatively, patients with a higher ddCD3 developed graft-versus-host disease more frequently, and when partially chimeric, had higher rates of conversion to full donor chimerism after withdrawal of immunosuppression. Early data from our small cohort of patients indicate that ddCD3 at 8 weeks may be used to guide decisions regarding withdrawal of immunosuppression and administration of donor lymphocyte infusion in partially T cell-depleted reduced-intensity regimens.
authors: Bone Marrow Transplant Program, Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298-0157, USA. atoor@mcvh-vcu.edu
authors: Amir A
authors: AA
authors: Toor
authors: Roy T
authors: RT
authors: Sabo
authors: Harold M
authors: HM
authors: Chung
authors: Catherine
authors: C
authors: Roberts
authors: Rose H
authors: RH
authors: Manjili
authors: Shiyu
authors: S
authors: Song
authors: David C
authors: DC
authors: Williams
authors: Wendy
authors: W
authors: Edmiston
authors: Mandy L
authors: ML
authors: Gatesman
authors: Richard W
authors: RW
authors: Edwards
authors: Andrea
authors: A
authors: Ferreira-Gonzalez
authors: William B
authors: WB
authors: Clark
authors: Michael C
authors: MC
authors: Neale
authors: John M
authors: JM
authors: McCarty
authors: Masoud H
authors: MH
authors: Manjili
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology; D017252:CD3 Complex / Q000276:immunology; D046528:Chimerism; D015331:Cohort Studies; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018655:Lymphocyte Count; D008212:Lymphocyte Depletion; D008875:Middle Aged; D011817:Rabbits; D012008:Recurrence; D015996:Survival Rate; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D017252:CD3 Complex; D007166:Immunosuppressive Agents